about
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United StatesClinical characteristics and outcomes of HIV-infected children diagnosed with Kaposi sarcoma in Malawi and Botswana.Beyond Endemic Burkitt Lymphoma: Navigating Challenges of Differentiating Childhood Lymphoma Diagnoses Amid Limitations in Pathology Resources in Lilongwe, MalawiClinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational StudyOutcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi.Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma.Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.Adolescent and young adult non-Hodgkin lymphoma.Differential proteomic analysis of endemic and sporadic Epstein-Barr virus-positive and negative Burkitt lymphoma.Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi.Spectrum of childhood Epstein-Barr virus-associated T-cell proliferations and bone marrow findings.Increasing Numbers of New Kaposi Sarcoma Diagnoses in HIV-Infected Children and Adolescents Despite the Wide Availability of Antiretroviral Therapy in Malawi.Quantifying bias in survival estimates resulting from loss to follow-up among children with lymphoma in Malawi.Hodgkin lymphoma, HIV, and Epstein-Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study.Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies.Tumoral bacillary angiomatosis in a child with human immunodeficiency virus.Risk factors and reasons for treatment abandonment among children with lymphoma in Malawi.Identifying opportunities to bridge disparity gaps in curing childhood cancer in Malawi: Malignancies with excellent curative potential account for the majority of diagnoses.Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment.Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi.Lessons From Pediatric HIV: A Case for Curative Intent in Pediatric Cancer in LMICs.Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives.Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortalityEndemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related diseaseKSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regionsProspective study of Burkitt lymphoma treatment in adolescents and adults in MalawiTranslation, psychometric validation, and baseline results of the Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures to assess health-related quality of life of patients with pediatric lymphoma in MalawiClinical trials to improve childhood cancer care and survival in sub-Saharan AfricaImpact of Protease Inhibitors on HIV-Associated Kaposi Sarcoma Incidence: A Systematic ReviewCheckmate for EBV-HLHNavigating the heterogeneous landscape of pediatric Kaposi sarcomaA clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North AmericaKaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome-like Clinical Presentation in Human Immunodeficiency Virus-infected Children in Malawi
P50
Q24617384-9BA073AD-8D6A-4167-86DA-4FAC6ED6A7E9Q33406437-7C38ACA9-F744-4091-ACF7-D6FADB88CC81Q33834535-725DE94D-1593-43C1-8221-8EC3FFC8D971Q35991165-ECCFDE99-5AA8-497E-A252-DC5444317352Q36944719-F5ADA030-2D4E-42CE-A5AF-922AF1244A2AQ38285265-E69BE06D-2F13-4C37-9E8D-68CE60D90C3CQ38379537-06595292-192A-4BBA-A0A9-0661163B8806Q38687541-BC8832D9-6EE3-4306-AD50-119DB9FBE011Q38806478-FEC1484E-2FC0-4CA0-86C1-126111B8F01AQ38932945-ECD9C33A-6162-4BD5-877C-65EC3C4BBE90Q40304324-1343022C-7C4D-4950-9EB1-1328C5AFB2E6Q40362145-81BE4E98-49EF-4161-9FBF-237F2D48814EQ40376023-4672ADFA-D872-4C30-8B3F-EEFFCA7FF929Q40451892-9657450A-A391-4F83-80AD-E7B7CB7C0185Q40485032-6396F93F-DF03-4AE8-88D4-915E3E0CB022Q41942675-E9ABFB06-480B-45B4-899D-9BFCFECEC1E4Q42202906-AE7ED240-33EA-4B48-A1CF-3388381101D3Q46608415-ACD06CD2-1F5A-4A31-92FF-AB78B9ACB058Q47391477-53369561-780E-44BE-96AD-1992EF94453EQ48117798-00E41704-FEBA-44E6-9A2E-FEA852A8EFEBQ49619413-FBB49A28-5684-45F3-B25A-8421E0425BB0Q50082299-0A310E8E-80F0-42AD-B468-6F69CFA6C244Q53686620-33E98EAF-1532-409B-8125-DE47948E8DA9Q58449857-7BA7B968-31EB-4196-AF44-D4CE63F308B3Q59137002-EFCAF93E-0819-4087-AA40-4BBEB6491CD5Q59352876-A0FCBA5C-F5A1-43FC-834E-4B2B8D5FF6D7Q62486734-06874D49-9757-4DAC-B0B1-0327C1BF03AAQ62489409-4ED18C6E-886F-4BC2-9F49-E42339D8A119Q62493534-515E8439-64B4-46D5-9E74-B0E1192C717FQ89474428-AB307FDD-D874-4180-9FFB-C8CC0D433CA2Q90263865-B9FD7F3D-0CE8-4125-B0B9-57EB7681DA1EQ92032743-49A41D26-A62A-4D0D-965C-7A59A7AD256CQ92104425-551DF16B-38AD-43D3-A07C-95F62FE00642Q92129644-98F8E75F-2140-4349-A68D-2010CC06F354
P50
description
researcher, ORCID id # 0000-0001-6115-1046
@en
wetenschapper
@nl
name
Nader K El-Mallawany
@ast
Nader K El-Mallawany
@en
Nader K El-Mallawany
@nl
type
label
Nader K El-Mallawany
@ast
Nader K El-Mallawany
@en
Nader K El-Mallawany
@nl
prefLabel
Nader K El-Mallawany
@ast
Nader K El-Mallawany
@en
Nader K El-Mallawany
@nl
P106
P31
P496
0000-0001-6115-1046